

Sub B1
Cont'd
Alcon

7.

(amended) Use of rivastigmine and excipients as defined in claim 1 in the manufacture of a medicament for the treatment of patients with mild to moderately severe Dementia of the Alzheimer's type by oral administration.

Use claims § 100 - 112, 2nd

REMARKS

Claims 3 to 7 have been amended to eliminate their multiple dependencies. In this connection, enclosed is an Appendix which represents a "marked-up" version of the changes made to Claims 3-7.

Favorable consideration of this application is respectfully requested.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593
(908) 522-6922

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

GRD/pk

Encl.: Appendix

Date: March 27, 2002

10089265-032700

APPENDIX

(Marked-up Version of the Changes Made)

3. (amended) Pharmaceutical composition according to claim 1 ~~or 2~~ wherein the outer film is permeable to water or body fluids.
4. (amended) Pharmaceutical composition according to ~~any one of~~ claims 1 ~~to 3~~ wherein the coating has a thickness of 50 to 800 micrometers.
5. (amended) A pharmaceutical composition according to ~~any one of~~ claims 1 ~~to 4~~ wherein said core releases an effective dose of the active agent 6 to 12 hours after ingestion.
6. (amended) A two pulse release pharmaceutical composition comprising a composition according to ~~any one of~~ claims 1 ~~to 5~~.
7. (amended) Use of rivastigmine and excipients as defined in ~~any one of~~ claims 1 ~~to 6~~ in the manufacture of a medicament for the treatment of patients with mild to moderately severe Dementia of the Alzheimer's type by oral administration.